Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy

Abstract

Dysregulation of adipocytokines may be associated with endothelial dysfunction in women with preeclampsia (PE), who are at increased risk of future cardiovascular disease. Visfatin, an adipocytokine with a potential cardiovascular role, is also known as nicotinamide phosphorybosil transferase (NAMPT). NAMPT gene polymorphisms affect circulating visfatin/NAMPT levels in obesity. Most findings provide evidence for increased visfatin/NAMPT circulating levels in PE. However, no previous study has tested the hypothesis that NAMPT polymorphisms affect visfatin/NAMPT levels in hypertensive disorders of pregnancy. We studied the effects of the NAMPT polymorphisms T>C (rs1319501) and A>G (rs3801266), and the haplotypes formed by them on visfatin/NAMPT levels and whether these genetic markers are associated with gestational hypertension (GH) and PE. We studied 212 healthy pregnant (HP), 181 patients with GH and 208 with PE. Genotypes were determined by Taqman allele discrimination assays. Plasma visfatin/NAMPT levels were measured by ELISA. No significant differences in visfatin/NAMPT levels were found among the groups. However, higher visfatin/NAMPT levels (P<0.05) were found in GH patients carrying the AG or the GG genotypes for the rs3801266 polymorphism or the 'T, G' haplotype. The TC and CC genotypes and the C allele for the rs1319501 polymorphism were more frequent in the HP than in the PE group (P<0.05). Moreover, the 'C, A' haplotype was also more frequent in the HP than in the PE group (P<0.01). Our findings suggest that although the rs3801266 polymorphism and the 'T, G' haplotype affect visfatin/NAMPT levels in GH, the rs1319501 polymorphism and the 'C, A' haplotype affect the susceptibility to PE.

Risk factors and potential protective factors of pregnancy‐induced hypertension in China: A cross‐sectional study

“…However, several limitations exist. We could only analyze factors with complete information in this retrospective research; therefore, some known factors could not be evaluated, such as hereditary factors, genetic variants, socioeconomic status, education, seasonal variation (climate), due to missing data ≥10% or not recorded in our database. As few women continue smoking or drinking alcohol during pregnancy, the effect of smoking habit, and alcoholic habit, on PIH cannot be evaluated.…”

Genetic Variants in Preeclampsia: Lessons From Studies in Latin-American Populations

“…Visfatin is an adipocytokine also known as nicotinamide phosphoribosyltransferase (NAMPT), which has a potential role in the pathophysiology of metabolic disorders such as hypertension and obesity (Dahl et al, 2012). A study by Luizon et al (2015) evaluated visfatin/NAMPT plasma levels in healthy pregnant women and in patients with gestational hypertension or PE, in the context of the NAMPT SNPs −423T < C (rs1319501) and rs3801266A < G in intron 1. No effects were observed concerning rs1319501.…”

“…No effects were observed concerning rs1319501. Nevertheless, gestational hypertensive patients carrying the rs3801266 “AG” and “GG” genotypes had higher visfatin/NAMPT levels compared to gestational hypertensive patients carrying the “AA” genotype (Luizon et al, 2015). Moreover, Luizon et al (2017) evaluated whether NAMPT SNPs (rs1319501T>C, rs3801266A>G), haplotypes and gene-gene interactions in the NAMPT pathway could affect plasma visfatin/NAMPT levels, and the response to antihypertensive therapy in PE and hypertensive pregnant women.…”

Can adipokine visfatin be a novel marker of pregnancy‐related disorders in women with obesity?

“…Luizon et al examined whether NAMPT polymorphisms or haplotypes affect plasma visfatin/NAMPT levels in the healthy pregnant, gestational hypertension and PE groups and whether they are associated with susceptibility to gestational hypertension and PE. The results suggest that rs3801266 polymorphism and ‘T, G' haplotype affect visfatin/NAMPT levels in gestational hypertension and the ‘C, A' haplotype and rs1319501 polymorphism affect the susceptibility to PE 143 . In other research carried out by the same research centre, it was found that NAMPT polymorphisms affect plasma visfatin/NAMPT levels in unresponsive PE patients.…”